Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27372053 | 1.00 | CA2 (0.48) | CA2CA1ACMSDPTGS2CA9 | |
| SCHEMBL27372235 | 0.76 | CA2 (0.46) | CA2CA1CA9CA12CA4 | |
| SCHEMBL31113619 | 0.75 | IKBKB (0.42) | CA2CA1PTGS2CA9CA12 | |
| SCHEMBL4406771 | 0.75 | MAOA (0.45) | ACMSDMAOA | |
| SCHEMBL28032548 | 0.73 | CA2 (0.73) | CA2CA1CA9CA12CA4 | |
| SCHEMBL971143 | 0.71 | CHRNB4 (0.49) | ACMSDPTGS2 | |
| SCHEMBL11034153 | 0.71 | CHRNB4 (0.49) | ACMSDFFAR2 | |
| SCHEMBL19910204 | 0.71 | CHRNB4 (0.49) | ACMSDPTGS2 | |
| SCHEMBL3233008 | 0.71 | ACMSD (0.44) | ACMSDPTGS2 | |
| SCHEMBL13782200 | 0.71 | CHRNB4 (0.49) | ACMSDPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | CA2 1909/4885CA1 2266/4885ACMSD 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.